In　this　work,　we　proposed　n　mu　PEF,　a　novel　pulse　configuration　combining　nanosecond　and　microsecond　pulses　(n　mu　PEF),　to　enhance　tumor　ablation　in　irreversible　electroporation　(IRE)　for　oncological　therapy.　n　mu　PEF　demonstrated　improved　efficacy　in　inducing　immunogenic　cell　death,　positioning　it　as　a　potential　candidate　for　next-generation　ablative　therapy.　However,　the　immune　response　elicited　by　n　mu　PEF　alone　was　insufficient　to　effectively　suppress　distant　tumors.　To　address　this　limitation,　we　developed　PPR@CM-PD1,　a　genetically　engineered　nanovesicle.　PPR@CM-PD1　employed　a　polyethylene　glycol-polylactic　acid-glycolic　acid　(PEG-PLGA)　nanoparticle　encapsulating　the　immune　adjuvant　imiquimod　and　coated　with　a　genetically　engineered　cell　membrane　expressing　programmed　cell　death　protein　1　(PD1).　This　design　allowed　PPR@CM-PD1　to　target　both　the　innate　immune　system　through　toll-like　receptor　7　(TLR7)　agonism　and　the　adaptive　immune　system　through　programmed　cell　death　protein　1/programmed　cell　death-ligand　1　(PD1/PDL1)　checkpoint　blockade.　In　turn,　n　mu　PEF　facilitated　intratumoral　infiltration　of　PPR@CM-PD1　by　modulating　the　tumor　stroma.　The　combination　of　n　mu　PEF　and　PPR@CM-PD1　generated　a　potent　and　systemic　antitumor　immune　response,　resulting　in　remarkable　suppression　of　both　n　mu　PEF-treated　and　untreated　distant　tumors　(abscopal　effects).　This　interdisciplinary　approach　presents　a　promising　perspective　for　oncotherapy　and　holds　great　potential　for　future　clinical　applications.　The　study　introduces　a　groundbreaking　pulse　configuration　termed　n　mu　PEF,　which　synergistically　employs　nanosecond　and　microsecond　pulses　to　trigger　cancer　cell　death　with　an　immunogenic　pattern.　Furthermore,　by　integrating　nanoenabled　immunomodulation,　n　mu　PEF　amplifies　the　systemic　immune　response　and　curbs　the　development　of　secondary　tumors,　thus　presenting　a　novel　outlook　for　oncological　therapy.image